Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsHere we select some of the classical literature in the field of chimeric antigen receptor technology. It is hoped that these reviews and research articles will help you to understand CAR technology quickly and keep up with the cutting edge development of this area.
Cell research 27, no. 1 (2017): 38-58.
Johnson, Laura A., and Carl H. June.
This paper reviewed the state of clinical gene-engineered T cell immunotherapy, its successes, challenges, and future. There is a coggle diagram in this paper summrized the completed and ongoing TCR and CAR gene-engineered T-cell immunotherapy clinical trail and all the tumor marker that used in these studies.
Science translational medicine 8, no. 355 (2016): 355ra116-355ra116.
Turtle, Cameron J., Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed Hawkins et al.
This article investigated the importance of T cell subset ratio in CAR-T cell thrapy. Immunotherapy with CD19 CAR-T cells in a defined CD4+/CD8+ ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progressionfree survival.
New England Journal of Medicine 371.16 (2014): 1507-1517.
Maude, Shannon L., et al
A review study of CD-19 CAR-T therapy in treatment of leukmia. Chimeric antigen receptor–modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed.
New England Journal of Medicine 368.16 (2013): 1509-1518.
Grupp, Stephan A., et al.
Follow-up study from University of Pennsylvania and Children’s Hospital of Philadelphia. Report two case of Chimeric Antigen Receptor–Modified T Cells use for Acute Lymphoid Leukemia treatment of two children. Complete remission was observed in both patients and is ongoing in one patient at 11 months after treatment.
New England Journal of Medicine 365.8 (2011): 725-733.
Porter, David L., et al.
A case report from University of Pennsylvania and Children’s Hospital of Philadelphia, which is about CD-19 CAR-T cells used in treatment of chronic lymphoid leukemia. Chimeric antigen receptor–modified T cells with specificity to CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL).
The Lancet 385.9967 (2015): 517-528.
Lee, Daniel W., et al.
A phase 1 dose-escalation clinical trial of T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia treatment in children and young adults. This work Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukemia. All toxicities were reversible and prolonged B-cell aplasia did not occur.
Cell research 27, no. 1 (2017): 38-58.
Johnson, Laura A., and Carl H. June.
This paper reviewed the state of clinical gene-engineered T cell immunotherapy, its successes, challenges, and future. There is a coggle diagram in this paper summrized the completed and ongoing TCR and CAR gene-engineered T-cell immunotherapy clinical trail and all the tumor marker that used in these studies.
Science translational medicine 8, no. 355 (2016): 355ra116-355ra116.
Turtle, Cameron J., Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed Hawkins et al.
This article investigated the importance of T cell subset ratio in CAR-T cell thrapy. Immunotherapy with CD19 CAR-T cells in a defined CD4+/CD8+ ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progressionfree survival.
New England Journal of Medicine 371.16 (2014): 1507-1517.
Maude, Shannon L., et al
A review study of CD-19 CAR-T therapy in treatment of leukmia. Chimeric antigen receptor–modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed.
New England Journal of Medicine 368.16 (2013): 1509-1518.
Grupp, Stephan A., et al.
Follow-up study from University of Pennsylvania and Children’s Hospital of Philadelphia. Report two case of Chimeric Antigen Receptor–Modified T Cells use for Acute Lymphoid Leukemia treatment of two children. Complete remission was observed in both patients and is ongoing in one patient at 11 months after treatment.
New England Journal of Medicine 365.8 (2011): 725-733.
Porter, David L., et al.
A case report from University of Pennsylvania and Children’s Hospital of Philadelphia, which is about CD-19 CAR-T cells used in treatment of chronic lymphoid leukemia. Chimeric antigen receptor–modified T cells with specificity to CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL).
The Lancet 385.9967 (2015): 517-528.
Lee, Daniel W., et al.
A phase 1 dose-escalation clinical trial of T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia treatment in children and young adults. This work Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukemia. All toxicities were reversible and prolonged B-cell aplasia did not occur.
Cell research 27, no. 1 (2017): 38-58.
Johnson, Laura A., and Carl H. June.
This paper reviewed the state of clinical gene-engineered T cell immunotherapy, its successes, challenges, and future. There is a coggle diagram in this paper summrized the completed and ongoing TCR and CAR gene-engineered T-cell immunotherapy clinical trail and all the tumor marker that used in these studies.
Science translational medicine 8, no. 355 (2016): 355ra116-355ra116.
Turtle, Cameron J., Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed Hawkins et al.
This article investigated the importance of T cell subset ratio in CAR-T cell thrapy. Immunotherapy with CD19 CAR-T cells in a defined CD4+/CD8+ ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progressionfree survival.
New England Journal of Medicine 371.16 (2014): 1507-1517.
Maude, Shannon L., et al
A review study of CD-19 CAR-T therapy in treatment of leukmia. Chimeric antigen receptor–modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed.
New England Journal of Medicine 368.16 (2013): 1509-1518.
Grupp, Stephan A., et al.
Follow-up study from University of Pennsylvania and Children’s Hospital of Philadelphia. Report two case of Chimeric Antigen Receptor–Modified T Cells use for Acute Lymphoid Leukemia treatment of two children. Complete remission was observed in both patients and is ongoing in one patient at 11 months after treatment.
New England Journal of Medicine 365.8 (2011): 725-733.
Porter, David L., et al.
A case report from University of Pennsylvania and Children’s Hospital of Philadelphia, which is about CD-19 CAR-T cells used in treatment of chronic lymphoid leukemia. Chimeric antigen receptor–modified T cells with specificity to CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL).
The Lancet 385.9967 (2015): 517-528.
Lee, Daniel W., et al.
A phase 1 dose-escalation clinical trial of T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia treatment in children and young adults. This work Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukemia. All toxicities were reversible and prolonged B-cell aplasia did not occur.
Cell research 27, no. 1 (2017): 38-58.
Johnson, Laura A., and Carl H. June.
This paper reviewed the state of clinical gene-engineered T cell immunotherapy, its successes, challenges, and future. There is a coggle diagram in this paper summrized the completed and ongoing TCR and CAR gene-engineered T-cell immunotherapy clinical trail and all the tumor marker that used in these studies.
Science translational medicine 8, no. 355 (2016): 355ra116-355ra116.
Turtle, Cameron J., Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek, Barbara Pender, Emily Robinson, Reed Hawkins et al.
This article investigated the importance of T cell subset ratio in CAR-T cell thrapy. Immunotherapy with CD19 CAR-T cells in a defined CD4+/CD8+ ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progressionfree survival.
New England Journal of Medicine 371.16 (2014): 1507-1517.
Maude, Shannon L., et al
A review study of CD-19 CAR-T therapy in treatment of leukmia. Chimeric antigen receptor–modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed.
New England Journal of Medicine 368.16 (2013): 1509-1518.
Grupp, Stephan A., et al.
Follow-up study from University of Pennsylvania and Children’s Hospital of Philadelphia. Report two case of Chimeric Antigen Receptor–Modified T Cells use for Acute Lymphoid Leukemia treatment of two children. Complete remission was observed in both patients and is ongoing in one patient at 11 months after treatment.
New England Journal of Medicine 365.8 (2011): 725-733.
Porter, David L., et al.
A case report from University of Pennsylvania and Children’s Hospital of Philadelphia, which is about CD-19 CAR-T cells used in treatment of chronic lymphoid leukemia. Chimeric antigen receptor–modified T cells with specificity to CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL).
The Lancet 385.9967 (2015): 517-528.
Lee, Daniel W., et al.
A phase 1 dose-escalation clinical trial of T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia treatment in children and young adults. This work Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukemia. All toxicities were reversible and prolonged B-cell aplasia did not occur.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
